I was merely explaining why the “expected high volume of ADRs” sentence isn’t necessarily something to be concerned about. But, regarding vaccine “side-effects” the initial safety review of the Pfizer vaccine will include data from 30,000 subjects plus other info. Part of its approval will be...
Yes, giving the drug to an unprecedented number of people world-wide will generate high volumes.
For example, about 1 billion people take aspirin annually. This has a range of ADRs such as rash, gastrointestinal ulcerations, abdominal pain. I imagine these are around the 5% mark i.e. aspirin...
Continued monitoring of approved drugs is standard practice; it’s part of pharmacovigilance. I’d be worried if this wasn’t happening, not worried it is.